Inhibidores de quinasas: nuevas herramientas en la lucha contra el cáncer - Bibliografía

1.Max Roser and Hannah Ritchie (2015) - "Cancer". Published online at OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/cancer' [Online Resource]

2. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

3. Tran, S., DeGiovanni, P. J., Piel, B., & Rai, P. (2017). Cancer nanomedicine: a review of recent success in drug delivery. Clinical and translational medicine, 6(1), 44. https://doi.org/10.1186/s40169-017-0175-0.

4. The two directions of cancer nanomedicine. Nat. Nanotechnol. 14, 1083 (2019). https://doi.org/10.1038/s41565-019-0597-5.

5. Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015). Targeting cancer with kinase inhibitors. The Journal of clinical investigation, 125(5), 1780–1789. https://doi.org/10.1172/JCI76094.

6. Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. (2018). Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular cancer, 17(1), 48. https://doi.org/10.1186/s12943-018-0804-2.

7. Jones L. H. (2018). Small-Molecule Kinase Downregulators. Cell chemical biology, 25(1), 30–35. https://doi.org/10.1016/j.chembiol.2017.10.011.

8. Ferguson, F. M., & Gray, N. S. (2018). Kinase inhibitors: the road ahead. Nature reviews. Drug discovery, 17(5), 353–377. https://doi.org/10.1038/nrd.2018.21.

9. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., … Zarrinkar, P. P. (2008). A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology, 26(1), 127–132. https://doi.org/10.1038/nbt1358.

10. Jannin, A., Penel, N., Ladsous, M., Vantyghem, M. C., & Do Cao, C. (2019). Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Critical reviews in oncology/hematology, 141, 23–35. https://doi.org/10.1016/j.critrevonc.2019.05.015.

11. Tillman, B. F., Pauff, J. M., Satyanarayana, G., Talbott, M., & Warner, J. L. (2018). Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. European journal of haematology, 100(4), 325–334. https://doi.org/10.1111/ejh.13020.

12. Tang, C., McMullen, J., & Tam, C. (2018). Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia & lymphoma, 59(7), 1554–1564. https://doi.org/10.1080/10428194.2017.1375110.

13. Girard N. (2018). Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?. Future oncology (London, England), 14(11), 1117–1132. https://doi.org/10.2217/fon-2017-0636.

14. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018). Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 29(suppl_1), i10–i19. https://doi.org/10.1093/annonc/mdx703.

15. Tang, Z. H., & Lu, J. J. (2018). Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer letters, 420, 242–246. https://doi.org/10.1016/j.canlet.2018.02.004.

16. Brown, B. P., Zhang, Y. K., Westover, D., Yan, Y., Qiao, H., Huang, V., Du, Z., Smith, J. A., Ross, J. S., Miller, V. A., Ali, S., Bazhenova, L., Schrock, A. B., Meiler, J., & Lovly, C. M. (2019). On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clinical cancer research: an official journal of the American Association for Cancer Research, 25(11), 3341–3351. https://doi.org/10.1158/1078-0432.CCR-18-3829.

17. Zhao, Z., & Bourne, P. E. (2018). Progress with covalent small-molecule kinase inhibitors. Drug discovery today, 23(3), 727–735. https://doi.org/10.1016/j.drudis.2018.01.035.

18. Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019). PROTACs: great opportunities for academia and industry. Signal transduction and targeted therapy, 4, 64. https://doi.org/10.1038/s41392-019-0101-6.